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Isotretinoin and Cutaneous Helper
T-Cell Lymphoma (Mycosis Fungoides)
John F. Kessler, MD; Stephen E. Jones, MD; Norman Levine, MD;
Peter J. Lynch, MD; Ann Rohman Booth, RN; Frank L. Meyskens, Jr, MD
\s=b\Retinoids, including isotretinoin, have demonstrated
antiproliferative and antineoplastic activity in laboratory
and clinical trials. In a phase II trial, 25 patients with
extensive mycosis fungoides were evaluated for
response to isotretinoin. There was a 44% (11 patients)
objective clinical response rate with three clinical com-
plete responses without concomitant evidence of patho-
logic clearing of the disease. An additional 24% (six
patients) showed a minor degree of clinical improvement.
The median time to response was two months (range, 0.5
to eight months) and the median response duration was
eight months or longer (range, one to 25 months). Chron-
ic toxic reactions consisted primarily of drying of the skin
and mucous membranes and resulted in dose reduction in
the majority of patients. It is concluded that isotretinoin
produces significant clinical benefit to some patients
with mycosis fungoides.
(Arch Dermatol 1987;123:201-204)
Vitamin A and its analogues, the retinoids, havedemonstrated antiproliferative activity in a
• number of malignant and premalignant conditions.15
In the laboratory, these agents can block phenotypic
cell transformation induced by radiation, chemical
agents, and growth factors."7 Additionally, they have
induced cellular maturation in promyelocytic leuke¬
mia and neuroblastoma cells in culture89 and have
demonstrated the capability to modulate a number
'
of immunologie functions, particularly cell-mediated
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cytotoxicity.1011 These promising features have
prompted clinical evaluation of these compounds in a
variety of cancerous and precancerous lesions as well
as in benign proliferative disorders.
For editorial comment see p 189.
Mycosis fungoides is an indolent cutaneous T-cell
lymphoma for which a number of partially success¬
ful treatments have been used, including electron
beam irradiation to the skin surface, topical mech-
lorethamine, and oral methoxsalen plus ultraviolet A
light (PUVA). We have previously reported our
experience with isotretinoin in a broad phase II
anticancer trial that included four patients with
mycosis fungoides, all of whom achieved an objective
response.12 Because of this encouraging initial experi¬
ence, we have treated 21 additional patients with
mycosis fungoides. In our total group there were
three complete responses and eight additional par¬
tial responses.
PATIENTS AND METHODS
Patients with clinically and histologically documented
mycosis fungoides or Sézary syndrome were eligible.
Pathologic evaluation included light microscopy, electron
microscopy, and immunopathologic study (indirect immu¬
nofluorescence with OKT3, OKT4, and OKT8) of skin
biopsy specimens (performed by N.L. or P.J.L.). All biop¬
sies were performed and specimens reviewed by University
of Arizona (Tucson) pathologists. All patients were
required to have at least advanced plaque stage disease(Committee on Staging and Classification of Cutaneous
T-Cell Lymphomas, skin stage T2 or greater).13 No exclu¬
sions were made for lymph node or visceral involvement,
previous treatment, or reduced performance status.
Informed consent was obtained in all cases in a protocol
approved by the University of Arizona Institutional
Review Board.
Patient evaluation included a history and physical
Table 1.—Characteristics of Patients* With
Mycosis Fungoides Treated With Isotretinoin
Characteristics No. (%)
Stage
Skin
Plaques (T2)
_
15 (64%)
Nodules (T3) 3 (12%)
Erythroderma (T4) 7 (27%)
Adenopathy
Present 10 (40%)
Absent 15(64%)
Visceral involvement 0 (0%)
Blood involvement 5 (20%)
Prior treatment
None 3(12%)
Topical steroids
_
20 (80%)
Prednisone 8 (32%)
Topical mechlorethamine
carmustine 7 (28%)
PUVAt 7 (28%)
Electron beam radiation therapy 8 (32%)
Systemic chemotherapy 9 (36%)
>3 modalities 10 (40%)
*The mean age of the patients was 65 years (range, 42 to 93 years).
There were 18 male and seven female patients.
tPUVA indicates oral methoxsalen plus ultraviolet A light.
examination, complete blood cell count and differential cell
count, examination of the buffy coat by light microscopy
for Sézary cells, routine fasting blood chemistry studies
and lipid profile, retinoid blood levels, color photographs of
skin involvement, and a baseline toxic reaction evaluation.
Appropriate roentgenograms and scans were obtained only
for suspected visceral involvement. Follow-up of patients
was generally at monthly intervals.
In the first 16 patients, treatment consisted of isotreti¬
noin initiated at a dose of 2 mg/kg/d orally in single or
divided doses. Reduction in dose was allowed in accordance
with previously published toxicity scales.14 Subsequent
patients were started at lower doses (1.0 mg/kg/d). Treat¬
ment was continued until disease progression or intolera¬
ble toxic reactions ensued. Response durations were calcu¬
lated from the time of initial response. The clinical response
criteria were as follows: A complete clinical response (CCR)
was defined as complete disappearance of all lesions lasting
at least four weeks. In those patients achieving a CCR, a
biopsy specimen of the previously most-involved areas was
obtained one month following a clinical complete remission.
A partial response (CPR) was at least a 50% decrease in
assessable lesions that lasted at least four weeks, while a
minor response involved definite improvement but less
than a CPR. Disease progression was characterized by the
unequivocal appearance of new lesions or a greater than
25% increase in size of the old lesions.
RESULTS
Twenty-eight patients were entered in the study.
Three were rendered ineligible because of a lack of
follow-up information (one patient) or because of
being reclassified on review as having the more
aggressive entity, peripheral T-cell lymphoma (two
patients). These two patients developed early viscer¬
al involvement and died shortly thereafter. The
Sixty-two-year-old man with extensive plaque-stage mycosis
fungoides over his entire body (his face was spared). Repre¬
sentative baseline photographs of his legs are shown at left. He
was started on a regimen of isotretinoin, 1 mg/kg/d, and
partial clinical response was noted after five months of therapy(center). Although his skin lesions subsequently completely .
cleared and clinical complete response was obtained (as
represented in photograph at right), biopsy specimen of previ¬
ously involved skin revealed residual atypical lymphocytes. His
clinical response continues with low-dose (10 mg daily) main-"
tenance ¡sotretinoin therapy for more than 21 months.
characteristics of the 25 assessable patients are
shown in Table 1. The mean age was 65 years, with a «.
range of 39 to 93 years. Eighteen patients were male
and seven were female. Skin involvement included
advanced plaques composed of more than 10% of the
skin surface in 15 patients, tumor nodules in three
patients, and erythroderma in seven patients. Palpa¬
ble adenopathy was present in ten patients: four of
these had lymph nodes that were soft and small. Two
patients underwent lymph node biopsy and speci¬
mens from both revealed involvement with atypicala
lymphocytes consistent with mycosis fungoides. No
patient had detectable visceral involvement. Blood
involvement with Sézary cells was found in five '
patients, with greater than 5% of circulating lym¬
phocytes in three patients. Seven patients had
received one prior treatment modality, six individu- *
als had received two, and ten had been treated with
three or more modalities. Two patients had not
received prior treatment.
There were 11 (44% ) objective clinical responses to
isotretinoin. An example of an objective clinical
response is shown in the Figure and described in the
legend. Three CCRs were noted with total disappear- "
anee of all visible skin lesions; however, random skin
biopsy specimens of previously involved skin
revealed residual atypical lymphocytes in the epider-  
mis. Eight patients achieved CPRs. Objective
responses occurred with advanced plaques (seven[43%] of 15) and with erythroderma (four of seven) <
but not with tumor nodules (T3) (zero of three).
There were three responses noted among the nine
patients who had received three or more prior treat¬
ments. Palpable adenopathy improved in the three
responders with palpable nodes; however, two of
these patients had small soft nodes, and the third
had no residual adenopathy following biopsy.
In addition to the 11 patients with significant
responses, there were six patients with minor
responses. The improvement in these latter patients
was characterized by reduction in pruritus and a
decrease in the degree of plaque infiltration but with
minor change in plaque area. Seven patients had no
response to the retinoid.
1 The time from initiation of treatment to clinical
response (CCR and CPR) ranged from two weeks to
eight months, with a median of two months. The
median duration of response (CCR and CPR) was
more than eight months, with a range of one to 25
months. Patients continued to receive isotretinoin as
, long as stabilization or response was clinically evi¬
dent.
TOXIC REACTIONS
The toxic reactions that were encountered are
shown in Table 2. Most problems involved drying of
the skin and mucous membranes and were usually
 controlled with emollients or reductions of the reti¬
noid dose. Additional effects included mild to moder¬
ate fatigue, arthralgias, myalgias, minor mental
status changes (usually irritability), and mild to
moderate headache.
The only laboratory change detected was in the
fasting serum triglycéride levels that occurred early
in the treatment course. The mean baseline triglyc¬
éride level was 205 mg/dL (2.31 mmol/L) (range, 89
to 395 mg/dL [1.00 to 4.46 mmol/L]) and the meanpeak triglycéride level with treatment was 463 mg/
dL (5.23 mmol/L) (range, 151 to 1485 mg/dL [1.70 to
16.77 mmol/L]). Posttreatment levels returned
promptly to baseline at 172 mg/dL (1.94 mmol/L)(range, 90 to 285 mg/dL [1.02 to 3.22 mmol/L]).
Individuals with initially elevated triglycéride levels
experienced the largest changes. No symptomatic
hypertriglyceridemia was encountered. There were
no treatment-related changes in cholesterol level,
liver enzymes, or renal function. One patient's serum
creatinine concentration increased with treatment
but was best ascribed to her underlying renal dis¬
ease. No hématologie toxic reactions were encoun¬
tered.
Dosage adjustments were needed in most patients,
usually due to skin and mucous membrane dryness or
fasting hypertriglyceridemia. Of the 16 patients
starting treatment with 2 mg/kg/d, 14 patients
required dose reductions (usually to about 1 mg/
kg/d), 12 for mucous cutaneous side effects and two
for markedly elevated hypertriglyceridemia. One
patient tolerated an increase in dose to 3 mg/kg/d.
Of six patients starting treatment with less than 2
mg/kg/d, two patients required dose reductions and
two tolerated increases. Responses were seen at all
dose levels whether initiated at 2 mg/kg/d or less.
Sustained responses as long as 15 months or more
have been noted with doses as low as 10 to 20 mg
daily in several patients whose plaques cleared at
Table 2.—Side Effects in 25 Patients Treated
With Isotretinoin
Percent of Patients
Toxic Reaction Mild Moderate Severe
Dry skin 36 36 20
Cheilosis 32 28
Conjunctivitis 20 36
Fatigue_16 12
Arthralgia/myalgia 20
Mental status change 16
Headache 20
higher doses but who were unable to tolerate these
higher levels because of continued cutaneous toxic
reactions.
COMMENT
We have demonstrated that isotretinoin produces
an objective clinical response rate of 44% (11
patients) with significant improvement in an addi¬
tional 24% (six patients) of patients with mycosis
fungoides. Similar results have been noted by others
using this retinoid and other derivatives as well.
Warrell et al15 reported responses in three of seven
patients treated with isotretinoin, and a report by
the Scandinavian Mycosis Fungoides Study Group
described objective responses in 19 of 24 patients
treated with isotretinoin.16 Mahrle et al,17 using an
arotinoid noted CCRs in three of five patients and
one CPR. Arotinoid responses occurred in the
plaque- and tumor-stage of the disease but not in one
patient with Sézary syndrome. Claudy and Rou-
chouse18 reported improvement in 11 patients with
parapsoriasis en plaques treated with the ethyl ester
retinoid derivative (Etretinate).18 Pathologically,
they noted clearing of intraepidermal infiltrates,
including Pautrier microabscesses. These studies
and our report substantiate that retinoids can sup¬
press or reverse the clinical manifestations of myco¬
sis fungoides.
As has been found with other dermatologie condi¬
tions, different retinoids may exhibit different
degrees of activity in the treatment of specific dis¬
eases. A large number of retinoids have been
developed using laboratory systems, many of which
exhibit more favorable therapeutic indexes than
isotretinoin. It remains to be determined whether
isotretinoin is the most active retinoid in mycosis
fungoides.
Retinoid treatment should probably not supplant
such standard treatment methods as electron beam
radiation therapy, a topical nitrogen mustard, or
PUVA, as these have resulted in long-term disease
control."20 The majority of patients relapse and
require further therapy, however, and retinoids may
be a relatively nontoxic, relatively effective alterna¬
tive. Cytotoxic therapy, while demonstrating activity
in this disease, is accompanied by considerable
potentially debilitating or even life-threatening toxic
reactions and is not considered curative.21
Other therapeutic strategies should also be
explored. Combinations of retinoids with interferon,
an active agent for the treatment of mycosis fun¬
goides,22 would be plausible, perhaps allowing dose
reductions of both agents. Additionally, the use of
retinoids in patients at high risk of relapse following
electron beam radiation therapy (ie, advanced dis¬
ease) should be evaluated as a maintenance regimen,
as has been successfully done with topical mechlore-
thamine.1'
Isotretinoin produces significant clinical response
of mycosis fungoides in heavily pretreated patients.
We recommend a starting dose of 1 mg/kg/d in two
divided doses. In some cases cutaneous toxic reac-
tions from the drug were initially difficult to distin¬
guish from progress or flare of the disease. In such
situations the dose was decreased by 50% to deter¬
mine the appropriate interpretation. The role of
isotretinoin in previously untreated patients
remains to be determined, but we recommend that
isotretinoin be used after more conventional simple
measures, such as topical steroids and perhaps
PUVA, have been exhausted. Alternatively, use of
isotretinoin with topical steroids may be well worth
considering. <
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